scispace - formally typeset
N

Nicolas Stifani

Researcher at Dalhousie University

Publications -  11
Citations -  421

Nicolas Stifani is an academic researcher from Dalhousie University. The author has contributed to research in topics: Motor neuron & Spinal cord injury. The author has an hindex of 8, co-authored 11 publications receiving 307 citations. Previous affiliations of Nicolas Stifani include Montreal Neurological Institute and Hospital & McGill University.

Papers
More filters
Journal ArticleDOI

Motor neurons and the generation of spinal motor neuron diversity

TL;DR: This article aims to provide a global view of MN classification as well as an up-to-date review of the molecular mechanisms involved in the generation of SpMN diversity and the acquisition of specific identity.
Journal ArticleDOI

Spinal microcircuits comprising dI3 interneurons are necessary for motor functional recovery following spinal cord transection.

TL;DR: It is suggested that dI3 interneurons compare inputs from locom motor circuits with sensory afferent inputs to compute sensory prediction errors that then modify locomotor circuits to effect motor recovery.
Journal ArticleDOI

Suppression of interneuron programs and maintenance of selected spinal motor neuron fates by the transcription factor AML1/Runx1.

TL;DR: These findings show an important role for Runx1 during the consolidation of selected spinal motor neuron identities and suggest a requirement for a persistent suppression of interneuron genes within maturing motor neurons.
Journal ArticleDOI

Spinal circuits for motor learning.

TL;DR: Application of cerebellar-derived principles to spinal circuitry leads to testable predictions of spinal organization required for motor learning.
Journal ArticleDOI

Kinematic gait parameters are highly sensitive measures of motor deficits and spinal cord injury in mice subjected to experimental autoimmune encephalomyelitis.

TL;DR: Kinematic gait analyses identified movement deficits before the onset of clinical signs in mice subjected to experimental autoimmune encephalomyelitis (EAE) that should assist the selection of promising therapeutic candidates for clinical testing in progressive MS.